Pancreatic Cancer Research

ResearcherSir Run Run Shaw HospitalActive in the last 2 years

Guixing Jiang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5053295937. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 8

  1. Camrelizumab Combined with Gemcitabine and Albumin-Bound Paclitaxel in Pancreatic Cancer Patients with Liver Metastases: A Prospective, Pilot Trial. Co-author DOI 10.2147/dddt.s568812↗
  2. SATB2 plays a critical role in pancreatic cancer cell proliferation, migration and T cell cytotoxicity. Co-author DOI 10.1016/j.cancergen.2025.06.006↗
  3. Icaritin and lenvatinib treatment for unresectable localized progressive pancreatic cancer: a report of six cases. Co-author DOI 10.1080/07853890.2025.2512436↗
  4. Immune-related gene SOX10 affects ferroptosis in pancreatic cancer and facilitates tumor progression by targeting CMTM7-mediated Wnt/β-catenin signaling pathwa… Co-author DOI 10.1186/s40001-024-02177-9↗
  5. High Expression of P38α and Preoperative Carbohydrate Antigen 19-9 Indicate Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.21683↗
  6. Integrated Analysis of Long Non-Coding RNA and mRNA Expression Profile in Pancreatic Cancer Derived Exosomes Treated Dendritic Cells by Microarray Analysis. Co-author DOI 10.7150/jca.21749↗
  7. A novel scoring system to analyze combined effect of lifestyle factors on pancreatic cancer risk: a retrospective case-control study. Co-author DOI 10.1038/s41598-017-13182-w↗
  8. Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Co-author DOI 10.18632/oncotarget.4924↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guoping Ding · 4 shared papers, 2015–2018 · strength 0.30
  2. Jiandong Zhang · 1 shared paper, 2026 · strength 0.30
  3. Xiaolong Liu · 1 shared paper, 2026 · strength 0.30
  4. Defei Hong · 1 shared paper, 2025 · strength 0.28
  5. Xiaolong Liu · 1 shared paper, 2025 · strength 0.28
  6. Jianguo Lu · 1 shared paper, 2025 · strength 0.28
  7. Liping Cao · 3 shared papers, 2017–2018 · strength 0.26
  8. Tianyu Lin · 1 shared paper, 2025 · strength 0.26
  9. Xiaofan Pu · 1 shared paper, 2025 · strength 0.26
  10. Tianyu Lin · 1 shared paper, 2025 · strength 0.26
  11. Jionghuang Chen · 3 shared papers, 2015–2018 · strength 0.23
  12. Shengnan Jia · 2 shared papers, 2018 · strength 0.18
  13. Liangjing Zhou · 2 shared papers, 2015–2018 · strength 0.13
  14. Tianshu Pang · 1 shared paper, 2017 · strength 0.08
  15. Zhengrong Wu · 1 shared paper, 2017 · strength 0.08
  16. Zhengrong Wu · 1 shared paper, 2015 · strength 0.05
  17. Liping Cao · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.